Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases

J. Neurochem. (2010) 114, 1651–1658.

[1]  P. Chan,et al.  Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice , 2010, Brain Research.

[2]  F. Cicchetti,et al.  Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[3]  F. LaFerla,et al.  Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood–brain barrier: An in situ cerebral perfusion study , 2009, Neurochemistry International.

[4]  S. Szabó,et al.  Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  R. Ferrante,et al.  Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. , 2008, Biochimica et biophysica acta.

[6]  J. Dominy,et al.  Discovery and Characterization of a Second Mammalian Thiol Dioxygenase, Cysteamine Dioxygenase* , 2007, Journal of Biological Chemistry.

[7]  R. de Kanter,et al.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.

[8]  B. Reusens,et al.  Is taurine a functional nutrient? , 2006, Current opinion in clinical nutrition and metabolic care.

[9]  M. Tremblay,et al.  Neuroprotective effects of cystamine in aged parkinsonian mice , 2006, Neurobiology of Aging.

[10]  T. Funatsu,et al.  Suppression of thiol exchange reaction in the determination of reduced-form thiols by high-performance liquid chromatography with fluorescence detection after derivatization with fluorogenic benzofurazan reagent, 7-fluoro-2,1,3-benzoxadiazole-4-sulfonate and 4-aminosulfonyl-7-fluoro-2,1,3-benzoxadia , 2006, Biomedical chromatography : BMC.

[11]  E. Hirsch,et al.  Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. , 2006, The Journal of clinical investigation.

[12]  R. Dubinsky,et al.  CYTE‐I‐HD: Phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[13]  M. Hayden,et al.  Treatment of YAC128 mice and their wild‐type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease , 2005, Journal of neurochemistry.

[14]  Francesca Cicchetti,et al.  Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease , 2005, Journal of the Neurological Sciences.

[15]  Arthur J. L. Cooper,et al.  Mechanism for the inhibition of transglutaminase 2 by cystamine. , 2005, Biochemical pharmacology.

[16]  C. Rock,et al.  Coenzyme A: back in action. , 2005, Progress in lipid research.

[17]  S. Hersch,et al.  Cystamine increases l‐cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation , 2004, Journal of neurochemistry.

[18]  M. Stipanuk,et al.  Regulation of cysteine dioxygenase and gamma-glutamylcysteine synthetase is associated with hepatic cysteine level. , 2004, The Journal of nutritional biochemistry.

[19]  J. Temsamani,et al.  Evidence for an active transport of morphine‐6‐β‐d‐glucuronide but not P‐glycoprotein‐mediated at the blood–brain barrier , 2003, Journal of neurochemistry.

[20]  S. Hersch,et al.  Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease , 2002, The Journal of Neuroscience.

[21]  Sawsan Youssef,et al.  Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine , 2002, Nature Medicine.

[22]  Christophe Rousselle,et al.  Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient Mice , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  P. Blanchet,et al.  Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABAA/benzodiazepine receptor complex and GABA content , 1999, Neurochemistry International.

[24]  S. Oja,et al.  Taurine as osmoregulator and neuromodulator in the brain , 1996, Metabolic Brain Disease.

[25]  J. Bourre,et al.  Taurine transport at the blood-brain barrier: an in vivo brain perfusion study , 1995, Brain Research.

[26]  H. Green.  Human genetic diseases due to codon reiteration: Relationship to an evolutionary mechanism , 1993, Cell.

[27]  C. L. Ursini,et al.  Enzymatic synthesis of S-aminoethyl-L-cysteine from pantetheine. , 1992, Biochimica et biophysica acta.

[28]  L. A. Wade,et al.  Cysteine and Cystine Transport at the Blood‐Brain Barrier , 1982, Journal of neurochemistry.

[29]  A. Lajtha,et al.  INHIBITION PATTERN BY ANALOGS INDICATES THE PRESENCE OF TEN OR MORE TRANSPORT SYSTEMS FOR AMINO ACIDS IN BRAIN CELLS , 1979, Journal of neurochemistry.

[30]  R. Katzman.,et al.  SYNTHETIC AMINO ACIDS AND THE NATURE OF l‐DOPA TRANSPORT AT THE BLOOD‐BRAIN BARRIER , 1975, Journal of neurochemistry.

[31]  B. Sörbo,et al.  Characteristics of the cysteinesulfinate-forming enzyme system in rat liver. , 1966, Biochimica et biophysica acta.

[32]  Beaumariage Ml,et al.  [RADIOPROTECTIVE ACTION OF CYSTEAMINE AND CYSTAMINE IN MICE AS A FUNCTION OF THE PERIOD OF TIME BETWEEN INJECTION OF THE PROTECTOR AND THE START OF X-RAY IRRADIATION]. , 1965 .

[33]  R. Scandurra,et al.  THE ENZYMATIC OXIDATION OF CYSTEAMINE TO HYPOTAURINE IN THE PRESENCE OF SULFIDE. , 1963, The Journal of biological chemistry.

[34]  Bruce A Barshop,et al.  Twice-daily cysteamine bitartrate therapy for children with cystinosis. , 2010, The Journal of pediatrics.

[35]  J. Dominy,et al.  Cysteamine dioxygenase: evidence for the physiological conversion of cysteamine to hypotaurine in rat and mouse tissues. , 2006, Advances in experimental medicine and biology.

[36]  R. Dawson,et al.  Building Biosynthetic Schools: Reviewing Compartmentation of CNS Taurine Synthesis , 2004, Neurochemical Research.

[37]  R J Huxtable,et al.  Physiological actions of taurine. , 1992, Physiological reviews.

[38]  C. Saller,et al.  gamma-Aminobutyric acid, glutamate, glycine and taurine analysis using reversed-phase high-performance liquid chromatography and ultraviolet detection of dansyl chloride derivatives. , 1989, Journal of chromatography.

[39]  R. Schwarcz,et al.  Anti-excitotoxic actions of taurine in the rat hippocampus studied in vivo and in vitro. , 1986, Advances in experimental medicine and biology.

[40]  H. Pasantes‐Morales,et al.  The role of taurine in nervous tissue: its effects on ionic fluxes. , 1981, Advances in experimental medicine and biology.

[41]  K. Kuriyama,et al.  A modulating role of taurine on release of acetylcholine and norepinephrine from neuronal tissues. , 1978, Japanese journal of pharmacology.

[42]  W H Oldendorf,et al.  Amino acid assignment to one of three blood-brain barrier amino acid carriers. , 1976, The American journal of physiology.